Since the reported success of anti-CD19 CAR T cell in treating ALL and CLL and approval of the first anti-CD19 CAR T cells therapy to treat B cell ALL and diffuse LBCL by the Food and Drug Administration (FDA), the number of clinical trials targeting several antigens other than CD19 using CAR T cells has dramatically increased (Kochenderfer et al., 2010a; Kalos et al., 2011; Porter et al., 2011; Mullard, 2017; Tang et al., 2018; Shah and Fry, 2019). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.